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Quality  adjusted  life  years  (QALYs)  offer  a measure  of  value  which  is advantageous  for  health  technology
appraisal  (HTA).  As  a composite  measure,  combining  length  of life  and  preference-based  self-reported
health  related  quality  of life  (HRQoL),  the  application  of  QALYs,  and  the  assessment  of value,  in oncology
and  cancer  care  can  be  challenging.  With  respect  to assessing  the  effectiveness  of  an  intervention  at
reducing  mortality,  clinical  trials  in oncology  predominantly  focus  on progression  free  survival,  whereas
overall  survival  is required  for  the  estimation  of QALYs.  This  is  further  complicated  by  crossover  trial
designs  which  have  become  common  in  oncology.  Evaluating  change  in  HRQoL  often  uses  generic  patientconomic evaluation
ecision making
utcome assessment
ALYs
atient reported outcomes (PROs)
reported  outcome  measures.  There  is  some  evidence  to suggest  that these  generic  measures  are  not
sensitive,  and perhaps  the  estimated  QALY  gain  does  not accurately  reﬂect  the  experience  of a  cancer
patient.  There  have  been  suggestions  that  we  broaden  the  deﬁnition  of  value  to  go beyond QALYs;  further
research  is required  to  consider  the  feasibility  of  this,  particularly  in the  context  of informed  decision
making,  when  faced  with  constrained  budgets.
©  2016  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND
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(. Introduction
Economic evaluation continues to become ever more important
or evidence-based decision making in healthcare systems. Health
echnology appraisal (HTA) systems have existed for many years in
ountries such as the UK, Netherlands, Germany, Australia, Canada
nd New Zealand [1,2]. HTA is now also being established in coun-
ries throughout Asia and South America, and in China and Russia
3]. HTA aims to establish the effectiveness and/or cost effective-
ess of health care technologies, in order to inform pricing and
eimbursement decisions.
Most of these HTA processes assess the cost effectiveness of an
ntervention in terms of its incremental cost per quality adjusted
ife year (QALY) gained. There are some notable exceptions to this,
uch as Germany and the United States (US)—see Box 1. Yet even in
he case of the US, the American College of Physicians has recently
alled for use of the cost per QALY approach to control drug costs
4].
QALYs are a measure of health outcomes which combine the
ength of time spent in a health state with the quality of life experi-
nced in that health state [5]. They have two principal advantages
s a measure of health for use in HTA. First, they provide a sin-
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gle metric to measure health, such that overall changes in health
can be measured and compared, whether they increase or decrease
HRQoL and whether they increase or decrease length of life. Second,
they facilitate comparisons of health outcomes and improvements
in health across different disease areas and treatments. The lat-
ter is particularly important when HTA is attempting to achieve
allocative efﬁciency in the allocation of health care budgets across
disease areas. That is, where the question is ‘what is the cost per
QALY gained of this new cancer medicine, relative to the cost per
QALY gained by spending that money in its next best use in other
clinical areas’.
As it is a composite measure, the estimation of QALYs entails
combining a number of different types of evidence, regarding:
a) the life expectancy of patients with the new treatment, com-
pared to existing treatments or placebo;
b) the self-reported health related quality of life (HRQoL) of
patients with the new treatment, compared to existing treat-
ments or placebo, using patient reported outcome (PRO)
questionnaires; and
(c) the weight to be attached to each aspect of HRQoL from the
perspective (by convention) of the general public, in order to
summarise the PRO data provided by patients.Each of these three elements of the evidence underpinning use
of QALYs reﬂect beliefs (value judgements) about what the aim of
the health care system is; what is considered to constitute ‘value’
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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Box 1: Exceptions to the rule: examples of two HTA sys-
tems that do not use QALYs − and why.
Germany
The Institute for Quality and Efﬁciency in health care (IQWiG)
considers the effectiveness and cost effectiveness of new tech-
nologies using a disease speciﬁc approach. New technologies
have to demonstrate their superiority against existing treat-
ments within the disease area. QALYs are not required as
IQWiG do not consider value for money across disease areas.
IQWiG’s methods guidelines note that while “a decision based
on a threshold per QALY gained is often presented as the inter-
national standard in health economics”, that this “should be
seen critically”. They emphasise that opting for cost per QALY
is not a real “methodological standard” as it rests on value
judgements, noting that the measure of overall beneﬁt arises
“not only as a methodological question”, but essentially a
value judgement and that the question as to whether QALYs
should be used involves ethical, legal, and cultural consider-
ations. They go on to question a number of the assumptions
underpinning the way quality of life weights are elicited and
used, concluding by noting “Ultimately, the following question
needs to be raised: How should resources in the health care
system be distributed? That is, on the basis of which rights,
claims or needs, with which aim, and which impact on the
allocation of goods or services? This question is only under-
stood as a value judgement, and this in turn determines which
scientiﬁc standards and methods should be applied” [6].
The US
Famously, the US literally outlawed use of the cost-per-QALY
approach as a basis for HTA. Legislation establishing the
Patient-Centered Outcomes Research Institute (PCORI) states
it “shall not develop or employ a dollars per quality adjusted
life year (or similar measure that discounts the value of a life
because of an individual’s disability) as a threshold to estab-
lish what type of healthcare is cost effective or recommended.
The Secretary shall not utilize such an adjusted life year (or
such a similar measure) as a threshold to determine the cover-
age, reimbursement, or incentive programs.” While there is
some use of cost effectiveness analysis in the US, Sullivan
et al. [7] note that it is “fragmented and uncoordinated, and
includes both the public and private sector”. The focus of HTA
in the US tends to be on relative effectiveness, rather than cost
effectiveness, so called comparative effectiveness.
Why do these differences arise in views on the appropriateness
of using the QALY? Torbica et al. [8], analysing the differences
between the US and ﬁve European HTA approaches, notes that
in each case “underlying culture and social values embed-
ded in the institutional context deeply inﬂuence and shape
the methods and use of health technology assessment and
f
a
a
t
h
u
a
b
2
f
o
i
icost-effectiveness analysis in healthcare decision making”.
rom health care; and from whose perspective it is to be measured
nd valued.
The aims of this paper are to (a) explain the way in which QALYs
re used as a measure of value of cancer treatments; (b) consider
he evidence in oncology relating to each of the steps noted above,
ighlighting a number of issues associated with the estimation and
se of QALYs in evaluating new cancer medicines; and (c) to discuss
spects of value from cancer treatments that may  not be captured
y QALYs, and how these might be taken into account.
. How are QALYs estimated?
In this section we brieﬂy describe the way QALYs are estimated
or use in HTA. Further detail on the use of PRO questionnaires in
ncology, and evidence on the relative merits of alternative PROs
n measuring and valuing the HRQoL of cancer patients, is provided
n section 4.Fig. 1. Example of QALY calculation with HRQoL beneﬁts.
PRO questionnaires are used to capture, in a systematic way,
patients’ self-reported health. They comprise a series of question
items, which can be scored and summarised in various ways to
characterise the patient’s health [9].
There are, in broad terms, two  types of PRO instrument: those
which aim to measure overall HRQoL (‘generic’) and those which
aim to measure health and health problems speciﬁc to a particular
disease (‘condition speciﬁc’). And within each of those, there are
two ways in which the question items may  be summarised: by a
scoring algorithm (e.g., adding up scores for each question) or by
‘preference weighting’. The latter is a requirement of QALYs: it takes
into account that some types of health problems (e.g. pain) carry
more weight than others (e.g. ability to perform usual activities),
and therefore that relief of those problems is of more value.
Some generic PROs, such as the EQ-5D [10–12], HUI [13] and
AQOL [14] are accompanied by sets of quality of life weights, or
‘utilities’, which are based on preferences and facilitate the esti-
mation of QALYs [15]. For this reason, such instruments are widely
employed for that purpose; for example, the EQ-5D is the preferred
instrument in NICE’s methods guidelines [16]. Condition-speciﬁc
instruments are generally not preference weighted – although
there is an increasing number of cases where preference weighting
has been provided for condition speciﬁc instruments, so that the
PRO data they provide can also be directly used in QALY estimation
[17,18]. Where preference weighting is not available for condition-
speciﬁc instruments, one option is to map  patients’ responses to
the question items on the condition speciﬁc PRO to the question
items on a generic PRO, and to use the preference weights avail-
able for the latter. Such mapping studies are common – but can
also be methodologically challenging [19].
QALYs are estimated by multiplying the length of life in each
health state by its HRQoL weight. The weights are on a scale
anchored at 1 (full health) and 0 (a health state so bad it is as bad
as being dead), with negative values indicating a health state con-
sidered to be worse than being dead. Each patients’ self-reported
health on a preference-weighted PRO can be summarised as over-
all HRQoL somewhere on that scale. That HRQoL weight is then
multiplied by the duration of that state to estimate the number of
QALYs.
For example, let’s assume a patient with cancer on current
treatment is to spend the next 5 years with no problems with
mobility, mild problems with self care, mild problems with usual
activities, severe problems with pain, and mild problems with anxi-
ety/depression (this is ‘proﬁle’ 12242 on the generic PRO, EQ-5D-5L
[20]), and then dies. The value of that state on the 0–1 scale is 0.552
and this equates to (5 × 0.55 = ) 2.76 QALYs [12]. This is the light
shaded box in Fig. 1. If they receive a new treatment after 6 months,
and this intervention reduces their pain (from severe to moderate,
which is ‘proﬁle’ 12232 on the EQ-5D-5L, value = 0.747) then they
N.J. Devlin, P.K. Lorgelly / Journal of Cancer Policy 11 (2017) 19–25 21
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Box 2: Directly elicited health state values.
Many HTA decisions are informed not just by PROs collected
in clinical trials or via observational studies, but also speciﬁc
health state valuation studies. Decision analytic models are
used to extrapolate beyond the trial, and health states within
these models require utility values in order to understand long-
term effectiveness and calculate QALYs over the lifetime [25].
The health states in these models are often quite speciﬁc,
and trial data and real world evidence (RWE) does not nec-
essarily exist which reﬂects the HRQoL experienced whilst in
these states. In this situation researchers develop health state
descriptors (from the literature and interviews with patients
and health professionals) and use stated preference techniques
like TTO or SG to elicit values from the general public [26].
Elicited preferences from the general public and patients can
be compared, which can highlight the divergence betweenig. 2. Example of QALY calculation with treatment detriments and life extension.
ould have (0.5 × 0.552 + 4.5 × 0.747 = ) 3.64 QALYs and their QALY
ain is (3.64 − 2.76 = ) 0.88. The interpretation of this is that the
mprovement in health over the 5 year period is equivalent to 0.88
f a year of full health, this is reﬂected in the shaded box in Fig. 1.
An issue with cancer is that often the side effects of treatment
an be so detrimental that it reduces the patients HRQoL dur-
ng a treatment phase, with the future expectation that it will
mprove their health in the long term. Expanding the example
bove, Fig. 2 shows the patient receiving, say, chemotherapy at
 months, for a period of 6 months. This results in them being
ired and fatigued, and they may  report severe problems with their
sual activities on the EQ-5D-5L. For that 6 month period their
ealth proﬁle is 12442, which equates to a value of 0.432 [12].
fter treatment they return to their prior state of usual activi-
ies, but with less pain, 12232 as before. Notably the treatment
lso extends their life for 1 year. Prior to this new treatment their
uality of life/life expectancy combination was estimated to give
.76 QALYs, with chemotherapy treatment they initially receive
 decrement in HRQol (0.5 × 0.433 = 0.217), then an increase in
RQoL and a life extension (5 × 0.747 = 3.73), the total QALYs are
0.5 × 0.552 + 0.217 + 3.73 = ) 4.22; the QALY gained from this treat-
ent (despite the side effects) is 1.463.
The HRQoL weights referred to above come from stated prefer-
nce studies. A sample of people – by convention, members of the
eneral public – are asked to imagine what it would be like to live in
ealth states described in terms of a given PRO. They are then asked
 series of questions designed to discover their preferences about
hich aspects of HRQoL described by that PRO are more important
o them. The preferences that are elicited from the sample are then
sed to model a ‘value set’ to provide HRQoL weights for all health
tates described by that PRO.
There are some important normative elements underpinning
hese methods. First, HRQoL weights generally come from mem-
ers of the general public, not from the cancer patients experiencing
he health state. The rationale is that it is the views of the general
ublic, as taxpayers and potential patients, which should be taken
nto account in decisions which affect the allocation of public sector
udgets between health care interventions [21]. However, alterna-
ive normative positions are possible. In Sweden, for example, the
TA body TLV prefers HRQoL weights based on the experience of
oor health [22]. The question of whether patients’ or the general
ublics’ values should be used in estimating QALYs has also been
onsidered in the literature [23].
There are also other normative elements of the methods. For
xample, there are a range of methods that can be used in stated
reference studies to establish HRQoL weights, e.g., visual analogue
cale, time trade off (TTO), standard gamble (SG), discrete choice
xperiments (DCEs). It is widely known that different methods yield
ifferent results, and that there is no gold standard (in the form ofsocietal preferences and patient preferences [27].
revealed preferences) available to assess which is ‘right’. The choice
of method is therefore largely driven by their acceptability to the
HTA body - see Box 2. This is potentially important, as the choice of
HRQoL weights (and methods underpinning them) can have a bear-
ing on estimates of QALY gains, and on conclusions about whether
observed differences in PRO measures of health between arms of a
clinical trial are statistically signiﬁcant [24].
An economic evaluation takes the QALY gains from an interven-
tion (‘incremental QALYs’) and compares them to the incremental
costs of an intervention (relative to a comparator). This produces an
incremental cost effectiveness ratio (ICER), often described as the
cost per QALY gained. While some technologies may be cost saving,
most, including most cancer medicines, are cost increasing. Judging
whether the improvements in QALYs justiﬁes that increase in cost
therefore requires a benchmark ‘cost per QALY’: a cost effective-
ness threshold. Technologies with an ICER below the threshold are
deemed good value for money; those over the threshold are more
likely to be rejected. The threshold is therefore critical to the use of
QALYs in HTA – but how to set that threshold is a contentious mat-
ter. It should reﬂect some understanding of what society is willing
to pay for health gains and the opportunity costs of new technolo-
gies within the health care budget – but evidence on these is often
weak. There is also the question of whether the threshold should
be the same for all disease areas – for example, does society value
a QALY gained by treating cancer more than a QALY gained from,
say, orthopaedic surgery? We  return to this issue in section 5.
3. Challenges in estimating improvements in survival in
cancer
QALYs rely on evidence on both quality of life and length of life.
Much of the evidence for new cancer medicines comes from clin-
ical trials. Trials typically run for 12–18 months, and measure, as
their primary endpoint, clinical indicators such as progression free
survival (PFS).
Evidence presented in the form of PFS presents some challenges
for economic evaluation, as the estimation of QALYs relies on evi-
dence of improvements in overall survival (OS), and clinical trials
rarely run for long enough to establish that. While it is possible
to follow up patients to systematically collect evidence on these
longer term effects on life expectancy, at the point a new medicine
is being considered in HTA, such evidence is unlikely to be available.
Consequently, the use of clinical trial evidence in cost effectiveness
studies requires analysts to estimate OS on the basis of intermediate
endpoints such as PFS, time to progression, etc. A variety of meth-
ods are available for this [28,29], all of which rely on assumptions
regarding the duration of treatment effects beyond the trial.
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Further, these estimations are complicated by ethical issues
elating to the response of patients enrolled in clinical trials. When
atients in the active or new therapy arm fail to respond, and their
ondition deteriorates, they are switched to the other therapy. This
reates ‘cross over’ effects which complicates analysis of the data
n the effectiveness of each treatment in extending longevity [30].
ach of these problems introduces a source of uncertainty into eco-
omic evaluation [31], with corresponding challenges for handling
hat in HTA decision making.
. Measuring patient reported outcomes in oncology
Oncology trials have, until recently, been dominated by the
ollection of clinical endpoints: tumour growth/response, PFS or
S, which are required for regulatory approval. There has been
n increasing awareness of the need to assess PROs in cancer
esearch, particularly given the side effects and toxicities of a num-
er of treatment regimes [32]. The most commonly used PROs are
he European Organisation for Research and Treatment of Cancer
EORTC) QLQ-C30 [33] and the Functional Assessment of Cancer
herapy – General (FACT-G) [34]. These instruments give summary
cores (for example the EORTC QLQ-C30 produces scores on func-
ional scales and symptom scales [35]) but are not preference-based
nd, therefore, cannot be used directly to estimate QALYs.
The use of generic preference-based measures, like the EQ-5D
r the SF-6D, in cancer research is not uncommon [36], but the
vidence of their validity and reliability is mixed [37]. Pickard et al.
36] in their review ﬁnd evidence that at least cross-sectionally the
Q-5D has been found to have construct validity and convergent
alidity in cancer studies. In terms of changes in health status –
ecall that change is a key feature of QALY estimation – then there
s variation across generic instruments. For example the EQ-5D is
ess sensitive to health status changes where vitality is an important
ttribute compared to the SF-6D [38], and vitality has been found
o be a signiﬁcant factor of cancer patients HRQoL [39,40].
In an attempt to merge the measures that focus on aspects of
ealth which are most relevant to patients, but generate QALY
stimates for health economic evaluations, researchers have under-
aken mappings or cross-walks between these cancer-speciﬁc
on-preference based measures and preference-based measures
41,42]. These mappings, however, have been found to be sensitive,
nd are likely to introduce further uncertainty into an economic
valuation which employs them to estimate QALYs [41]. An alter-
ative to mapping, that is growing in popularity, is the development
f condition-speciﬁc preference-based measures (CSPBM) [43].
peciﬁcally for cancer two CSPBMs currently exist, the EORTC-8D
17] and the QLU-C10D [18].
The EORTC-8D was derived using Rasch and factor analysis from
esponses to the EORTC QLQ-C30 by multiple myeloma patients.
t has eight dimensions: physical functioning, role functioning,
ain, emotional functioning, social functioning, nausea, fatigue and
leep disturbance, and constipation/diarrhoea, each with four lev-
ls except physical functioning which has ﬁve levels. This results in
1,920 unique health states, which were valued using a time trade-
ff approach in healthy individuals from the North of England. The
tility values range from 0.292 to 1.00 [17]. In a subsequent analysis
omparing the EQ-5D, the EORTC-8D and mapped EQ-5D utility val-
es, Rowen et al. [44] found that the EQ-5D consistently generated
he highest utility values, and most notably was more responsive
hen discriminating according to severity than the EORTC-8D. This
upports the earlier ﬁndings by Pickard et al. [36], however, Rowen
t al. did ﬁnd that 13% of EQ-5D responses are at full health when
he EORTC-8D suggests problems on dimensions such as fatigue
nd physical functioning. Lorgelly et al. [45] also found similar ceil-
ng effects, 40% of the responses for the fatigue dimension are notancer Policy 11 (2017) 19–25
at level 1 when their EQ-5D proﬁles suggests they are in full health;
this is suggestive of a problem with content validity in the EQ-5D.
Lorgelly et al. additionally ﬁnd that the EORTC-8D produces out-
come values that are as valid, responsive and sensitive as the EQ-5D,
but that the EORTC-8D values are higher, although this is likely
driven by the fact that the EQ-5D has a much greater range of val-
ues (-0.59 to 1.00). When estimating change over time, i.e. QALYs,
they ﬁnd that the scale effect is translated in the QALY estimates,
whereby condition-speciﬁc QALYs (those using the EORTC-8D)
were signiﬁcantly higher than those derived from differences in the
EQ-5D-3L over time. Both QALYs estimates were found to be sim-
ilarly sensitive to a number of patient and disease characteristics,
although the difference in QALYs was  most sensitive for patients
with lower HRQoL, those with declining functionality and in partic-
ular sites, such that the authors advise caution for both researchers
and decision makers utilising QALYs estimated from the EORTC-8D
if their target group includes such patients [45].
The QLU-C10D [18] is a much more recently developed PRO.
An international collaboration of researchers pooled 18 datasets
across a range of tumour sites, stages and treatments, to which
they applied conﬁrmatory factor analysis and Rasch analysis. They
then sought patients’ opinions on the relative importance of items,
to ultimately design their ten dimension descriptive system. The
approach is an extension of Rowen et al. [17]. The resulting instru-
ment has the same dimensions plus two further ones (sleep and
appetite), four of the dimensions are identical (emotional function-
ing, fatigue, nausea, bowel problems), one contains the same items
but different levels (physical functioning) and three contain differ-
ent items (role functioning, social functioning, pain). Notably they
suggest the use of QLU-C10D over the EORTC-8D, as it is based on a
broader spectrum of patients and has been endorsed by the EORTC
QOL Group. Valuations generated using a DCE [46], are forthcoming
and will be important for the validation of the instrument.
An alternative to CSPBM is to reﬁne generic MAUIs by adding on
dimensions and/or levels. Adding dimensions is often described as
bolt-ons [47]. Previous research has considered adding dimensions
for cognition [48], sleep [49], and vision, hearing and tiredness [47]
to the EQ-5D. To date the results of these studies are variable, with
the bolt-on dimension sometimes impacting the EQ-5D depend-
ing on the level of the additional dimension [47]. More research is
required if bolt-ons are to have any effect on the way  QALYs are
estimated. Increasing the number of levels in a generic instrument
may  improve its sensitivity. The EQ-5D recently expanded from 3
levels (3L version) to 5 levels (5L version) [20]. Early evidence has
shown that the 5 level system has fewer ceiling effects and greater
discriminatory power in cancer patients [50,51].
All of the options discussed above require self-completion of
PRO measures. Cancer patients are often severely ill, may be in
palliative care or at end-of-life, and unable to self-complete/self-
report. Proxy reporting is possible, by a carer or health professional,
but this introduces an element of uncertainty. It may be neces-
sary to understand multiple proxy perspectives, which further adds
complexity [52]. To date there is limited evidence of the reliabil-
ity of proxy reporting for generic measures or condition-speciﬁc
measures [53–55]. As end of life issues continue to persist, more
research on proxy reporting will be required.
5. Limitations of QALYs in capturing value, and ‘going
beyond QALYs’
As we noted above, there is some evidence that there are limita-
tions with the generic PROs currently used as a basis for estimating
QALYs. This is perhaps not surprising, given that generic PROs such
as the EQ-5D are designed to capture HRQoL across disease areas, in
order to enable comparisons of value for money. This suggests that
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here may  be a need for further research to ensure that current uses
f PROs in cancer are not systematically missing some domains of
ealth related quality of life that are important to understanding
he beneﬁts and side effects of new cancer treatments. However, a
ider question is whether there are attributes of the value of new
ancer treatments which are missed entirely due to the reliance on
ALYs as a measure of value.
The use of QALYs in HTA rests on extra-welfarism [21,56,57] and
he value judgement that resource allocation within the health care
ector is primarily aimed at maximising improvements in health
rather than social welfare more broadly) [58]; and that QALYs
epresent a pragmatic means of measuring health for that pur-
ose. What else, other than improvements in length and quality of
ife, might matter to patients, or indeed society, when considering
hether new cancer medicines are good value for money?
First, it is important to note that QALYs are a measure of health
utcomes from treatment – and take no account of patients’ pref-
rences with respect to the ‘process of care’ [59,60]. For example,
t may  be that a treatments which can be delivered at home, or
hich minimise hospital visits, or are less invasive, have an impor-
ant value to patients. There is growing interest in taking patients’
references into account – but as yet, little consensus on the ways of
oing so, and how HTA can weigh up such considerations alongside
ALYs.
Second, it is possible that patients may  have different prefer-
nces with respect to the domains of HRQoL than do the general
ublic [23]. For example, evidence from the ﬁeld of subjective well-
eing and behavioural economics suggests that the general public
ssign lower values to chronic health states than do the patients
xperiencing them, due to patients’ adaptation to their conditions.
n the other hand, stated preference studies involving the general
ublic suggest their ‘affective forecasting’ of the impact of mental
ealth problems such as depression, underestimate the impact of
hese conditions on subjective wellbeing, relative to the views of
atients experiencing those problems [61,62].
Third, there may  be wider beneﬁts to society from treating can-
er. For example, the reduced mortality and morbidity from cancer
ay  enable cancer patients to return to work more quickly, or
o contribute in other (non-income earning) ways to society, for
xample by caring for others or undertaking voluntary work. Sim-
larly, improvements to the health of cancer patients may  also
elieve the burden on their (informal) caregivers, improving their
RQoL and ability to work. In cost beneﬁt analysis, all such beneﬁts
ould be recognised as relevant − whereas under the more restric-
ive perspective typically adopted in HTA, these are not generally
onsidered [56].
Finally, it is important to recognise that societal decisions
egarding the allocation of health care resources will be contin-
ent not just on how much health (or other beneﬁt) is produced,
ut also how it is distributed. The simple, utilitarian ‘QALY maximi-
ation’ approach is unlikely to represent the reality of the complex
nd multiple objectives at work in the health care system. And allo-
ating resources based solely on the criteria of cost-per-QALY is
nlikely to achieve allocative efﬁciency, given that society at large
erives value from things other than (or additional to) QALYs [63],
nd has preferences over their distribution as well as their total
um [64].
While these criticisms of the QALY maximisation approach have
een made many times before (for example, Broome [65], and
ore recently Kind [66]), there may  be speciﬁc reasons why  these
re particularly relevant to decisions regarding the allocation of
esources to oncology medicines, and the priority to be accorded to
he treatment of cancer relative to other illnesses.
For example, it may  be argued that society places a special
alue on cancer medicines (that is, that society is willing to giveancer Policy 11 (2017) 19–25 23
up more of other things, including the improvement of health of
other patients) because:
• Cancer is a ‘dread’ disease; one upon which society may therefore
place a premium value to the reduction of mortality and morbidity
from it, compared to other diseases of similar severity;
• Related to the idea of ‘dread’ disease is the idea that here may
be value to society, and for those diagnosed with the condition,
in the hope of effective treatments − over and above their actual
therapeutic effects. This is analogous to the concept, in classical
welfare economics, of ‘option value’ For a paper exploring this as
a potential source of value, see Lakdawala et al. [67];
• Finally, cancer medicines often (although not always) affect peo-
ple’s length and quality of life at the end of their life. There may
be societal preferences for prioritising the treatment of end of life
conditions, or severe conditions with greater priority [68,69].
The implication of these factors is that there are things other
than QALYs which might justiﬁably be taken into account in HTA,
in order to capture the beneﬁts of treatments for cancer (and other
technologies). In the following section, we discuss how this might
be done in HTA.
6. Challenges in going ‘beyond QALYs’ in value assessment
The challenge with extending, beyond QALYs, what is consid-
ered in assessments of value and value for money is how to combine
completely different sorts of evidence, to enable a weighing up of
beneﬁts against costs.
HTA bodies such as NICE currently rely on a deliberative process
to weigh up quantitative evidence on cost per QALY alongside other
considerations they deem relevant [70]. Deliberative processes are
argued to have some important advantages in HTA, allowing deci-
sion makers to be ﬂexible and to exercise ad hoc judgements as
they consider appropriate [71,72]. However, a problem with this
approach is that the importance that decision makers assign to
these different aspects of beneﬁt is not transparent. This risks a
lack of consistency between decisions over time (and in NICE’s
case, between the decisions of its HTA committees). It potentially
reduces accountability to stakeholders (e.g. tax payers and patients)
and fails to give clear signals to the life sciences industry about (a)
what is considered to be of value to the health care system and
therefore (b) where they should prioritise research and develop-
ment (R&D) effort [70]. For example, Dakin et al. [73], modelling
the likelihood of NICE recommending for or against new technolo-
gies, ﬁnd that the odds of NICE recommending in favour of a new
technology is 3.1 higher for cancer medicines − but note that the
ability to model or predict NICE decisions is hampered by the fact
that NICE may  be taking into account factors that are not reported
or readily quantiﬁable. It is clear that considerations other than
QALYs are being taken into account in HTA − but not how much
importance is placed on these other considerations.
There are a variety of means by which these other aspects of
value might be taken into account in a more systematic way along-
side QALYs:
a) QALYs could be ‘weighted’ to reﬂect any differences in value
society places on QALY gains by some patients/diseases, where
that is supported by evidence regarding social preferences;
b) Both QALYs and other aspects of beneﬁt from cancer medicines
could be monetised, using willingness to pay studies, and mone-
tary measures of beneﬁt weighed up alongside costs, using cost
beneﬁt analysis;
(c) QALYs gained could be considered alongside other, quantiﬁed
aspects of beneﬁt, and combined in a way that reﬂects the trade-
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offs people are willing to make between them − and then an
aggregate measure of beneﬁt is considered alongside cost. There
is a set of methods available to facilitate this, known as multiple
criteria decision analysis (MCDA) [70].
There is growing interest in the use of MCDA to support HTA
ecision making [74,75] and a number of pilots have already been
ndertaken in HTA systems such as Germany, Italy, the Philippines
nd Israel [76]. There is however, some caution about adopting the
se of MCDA in HTA, on the grounds that it limits the ability of HTA
ommittees to exercise judgement. Further, there are important
ssues still to resolve − not least, the means by which the opportu-
ity cost of new medicines (e.g. in oncology) are to be weighed up
gainst the beneﬁts foregone to other patients.
. Conclusions
QALYs, and their use in HTA, are well established internationally,
nd implementation of this approach continues to expand around
he world − including in the emerging (China; Brazil) and exist-
ng markets (notably, the US, where anti-QALY sentiment appears
urrently to be changing). They are of critical importance for the
ncentives to global pharma to direct investment in oncology R&D.
There are, nonetheless, legitimate concerns about the reliance
n measures of QALYs to capture all relevant aspects of beneﬁt from
ancer treatments − both from the perspective of patients (aspects
f HRQoL not adequately captured from PROs; preferences with
espect to the process-of-care, independent of effects on HRQoL)
nd from society (relating to cancer as a dread disease; the value of
hope’; other equity considerations; and impacts on HRQoL beyond
hose of the patient (eg caregivers) and any spill over effects of
mproved health on productivity).
Broadening the deﬁnition of value to be used in HTA of cancer
herefore has prima facie justiﬁcation. However, to do so requires
areful consideration of (a) the feasibility of measuring these other
lements of value in a systematic way; (b) the acceptability and
ransactions costs of measuring, valuing and incorporating these
hings into existing HTA decision making processes; and (c) the
mportance, in budget-constrained health care systems, of consid-
ring not just value obtained from new cancer medicines, but also
alue foregone in other disease areas.
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